# Ultrasound in cardiovascular care: a perspective on preventive, diagnostic, and monitoring applications

**Authors:** Yoram Chaiter, Daniel Lyon Fink, Yossy Machluf

PMC · DOI: 10.3389/fcvm.2026.1721700 · Frontiers in Cardiovascular Medicine · 2026-02-18

## TL;DR

Ultrasound is being repositioned as a key tool in cardiovascular care for prevention, diagnosis, and monitoring, especially with advances in AI and portable systems.

## Contribution

The paper highlights ultrasound's evolving role in cardiovascular medicine, emphasizing its integration with AI and mobile health for personalized care.

## Key findings

- Ultrasound enables early detection of vascular changes and monitoring of atherosclerosis across multiple arteries.
- AI and portable ultrasound systems are expanding access and improving diagnostic accuracy in cardiovascular care.
- Ultrasound can enhance patient engagement and serve as a behavioral catalyst for preventive care.

## Abstract

Cardiovascular disease (CVD) remains the leading global cause of death, underscoring the need for improved strategies for early detection and prevention. Conventional risk models such as Framingham and SCORE estimate population-level risk but often fail to identify individuals with subclinical vascular damage. Atherosclerosis, the underlying cause of most CVDs, develops silently for decades, emphasizing the importance of imaging modalities capable of detecting early vascular changes. Ultrasound offers a safe, non-invasive, and radiation-free means to visualize vascular structure, function, and hemodynamics in real time. This perspective reframes ultrasound as a cornerstone of preventive and diagnostic vasculature medicine in general, and cardiovascular medicine in particular, emphasizing major modalities—point-of-care ultrasonography (POCUS), Doppler, Duplex, contrast-enhanced ultrasound (CEUS), elastography, and pulse wave velocity (PWV). These techniques enable early risk stratification, monitoring of atherosclerotic progression, and evaluation of therapeutic response across carotid, aortic, peripheral, coronary, cerebral, and renal arteries. Ultrasound also serves as a behavioral catalyst, enhancing patient awareness and engagement. However, widespread adoption requires standardized protocols, provider training, ethical oversight, and equitable implementation to avoid global disparities. Recent advances in artificial intelligence (AI), machine learning (ML), and deep learning (DL) are revolutionizing ultrasound by automating plaque quantification, improving reproducibility, and expanding access through portable and handheld systems. Cloud-based interpretation and telemedicine integration further extend cardiovascular screening into community and home settings. As ultrasound evolves into a frontline technology for prevention, diagnosis, and monitoring, its integration with AI-driven interpretation and mobile health platforms positions it as a pivotal tool in personalized and equitable cardiovascular care.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), atherosclerosis (MONDO:0005311)

## Full-text entities

- **Diseases:** PAD (MESH:D058729), renal impairment (MESH:D007674), thromboembolic occlusion (MESH:D013923), myocardial dysfunction (MESH:D006331), CAD (MESH:D003324), CVD (MESH:D002318), RAS (MESH:D012078), myocardial infarction (MESH:D009203), ischemic stroke (MESH:D002544), familial hypercholesterolemia (MESH:D006938), deep venous thrombosis (MESH:D020246), cardio-cerebrovascular disease (MESH:D002561), vascular damage (MESH:D057772), AAA (MESH:D017544), abnormal vascular function (MESH:D000014), restenosis (MESH:D023903), carotid artery disease (MESH:D002340), death (MESH:D003643), hypertensive (MESH:D006973), Atherosclerosis (MESH:D050197), intracranial stenosis (MESH:D003251), AI (MESH:C538142), left ventricular dysfunction (MESH:D018487), obese (MESH:D009765), DL (MESH:D007859), stroke (MESH:D020521), aneurysm (MESH:D000783), Vascular failure (MESH:D051437), calcification (MESH:D002114), plaques (MESH:D003773), valvular disease (MESH:D006349), vascular disease (MESH:D014652), ischemic (MESH:D002545), diabetes (MESH:D003920), plaque rupture (MESH:D012421), chronic mesenteric ischemia (MESH:D065666), aortic aneurysm (MESH:D001014), anxiety (MESH:D001007), arterial lesions (MESH:D020765), endoleaks (MESH:D057867), vascular inflammation (MESH:D007249), MASLD (MESH:D008107), carotid artery plaques (MESH:D016893), cirrhosis (MESH:D005355), coronary lesions (MESH:D003327)
- **Chemicals:** lipid (MESH:D008055)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957240/full.md

## References

131 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957240/full.md

---
Source: https://tomesphere.com/paper/PMC12957240